



People's Democratic Republic of Algeria
Ministry of Higher Education and Scientific Research
Mohamed Khider University – Biskra
Faculty of Exact Science
Computer Science Department



Revolutionizing Lung Cancer Diagnosis with LungPathAI: An AI-Powered Digital Pathology Platform

Presented by:

- GUESBAYA Islem
- CHERIFI Kacem
- OUAMANE Takieddine

Supervised by:

- BELAALA Abir

Academic year : 2024 – 2025

Table of contents

01

Introduction

02

Problematic & Objective

03

Related Work

04

Methodology

05

Experimental Results

06

Platform Development

07

Conclusion



01


Introduction

Introduction

Lung cancer is a major health concern in Algeria.

In 2022, it ranked among the most diagnosed cancers, with **5,040 new cases**.

Among men, it had the **highest cancer-related death rate**, with an incidence of **19.5** and mortality of **17.9 per 100,000** (GLOBOCAN, 2022).



Cancer Statistics in Algeria (2022)

World Health Organization



Number of new cases

64 713

Number of deaths

35 778


Number of prevalent cases
(5-year)

177 718

Statistics at a glance, 2022

	Males	Females	Both sexes
Population	22 912 687	22 437 454	45 350 141
Incidence*			
Number of new cancer cases	29 387	35 326	64 713
Age-standardized incidence rate	130.6	152.2	141.2
Risk of developing cancer before the age of 75 years (cum. risk %)	14.1	15.1	14.6
Top 3 leading cancers (ranked by cases)**	Lung Colorectum Prostate	Breast Colorectum Thyroid	Breast Colorectum Lung
Mortality*			
Number of cancer deaths	18 809	16 969	35 778
Age-standardized mortality rate	82.7	73.1	77.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.7	7.8	8.2
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Bladder	Breast Colorectum Cervix uteri	Breast Lung Colorectum
Prevalence*			
5-year prevalent cases	72 408	105 310	177 718


Lung
Colorectum
Bladder



Breast
Lung
Colorectum

Introduction | Lung Cancer Types


Lung Cancer Types



Adenocarcinoma



Squamous Cell Carcinoma



Large Cell Carcinoma

Introduction | TRADITIONAL SLIDE DIAGNOSIS



Limitations of Traditional Lung Cancer Diagnosis



Time-intensive Process

- Manual examination of tissue samples creates significant diagnostic delays.




Diagnostic Variability

- Substantial inter-observer differences among pathologists affect consistency.



Volume Challenges

- Rising cancer incidence is overwhelming existing diagnostic capacity.



Limited Standardization


- Inconsistent sample preparation and interpretation practices across institutions




02

Problem Statement

AI Solutions in Literature: Limitations



Proposed Solution





03

Related Work

Overview of Leading MIL Methods

Approach	Year	Learning Paradigm	Training/Inference Speed	Clinical Interpretability Quality
CLAM	2021	Weakly Supervised + Clustering	Moderate/Fast	Good
TransMIL	2021	Correlated instance learning	Slow/Moderate	Normal
DSMIL	2021	Self-supervised + supervised	Fast/Fast	Normal
CAMIL	2025	Channel-aware feature learning	Moderate/Fast	Normal

Our work

1

Adopt CLAM architecture to classify lung cancer subtypes.

2

Train and Evaluate the model using the public CPTAC dataset.

3

Generate heatmaps highlighting regions of interest (ROIs) using attention scores.


4

Integrate the model into a web application.


5

Validate heatmaps quality by comparing model outputs with pathologist-provided annotations.

Why Not Traditional CNN ?



WSI




Convolutional Neural Network

04


Methodology

Operational steps




1- Data Acquisition


Data-set Description




Data-set Split




2- Preprocessing



Step 1 : Removing background and Patching





Whole slide image : a high-resolution digital pathology image (in svs format).





Grayscale image

Segmentation process
(removing background)



segmented tissue

Patching process



Output : 256*256 pixels
extracted patches saved in
HDF5 format


Segmentation Params

Parameter	Value	Description
Segmentation Level	-1	Resolution level used for segmentation -1 indicates the lowest available resolution level in the WSI
Saturation Threshold	8	determine if a pixel belongs to tissue based on its color saturation
Close	4	Size of the morphological closing operation to fill small holes and gaps in tissue regions
Area Threshold	100	Minimum area threshold for keeping a tissue region. Regions smaller than this are removed
Area holes	16	Minimum hole area to be considered for removal from tissue mask
Max_n_holes	8	Maximum number of holes allowed per tissue region


Patching Params

Parameter	Value	Description
Patch Level	0	The resolution level of the WSI from which patches are extracted (0 is for the best details)
Patch Size	256	Size of each patch
Step Size	256	This control how far to move when extracting the next patch it determines the overlap between adjacent patches


Step 2 : Feature Extractions



What is Next ?



WSI




patches



Instance features



Bag Of Instance



3- Deep Learning Model

Single-Branch




Multi-Branch



Components	Single Branch	Multi Branch
Attention Branches	Single Attention Pathway (one attention score per patch)	Multiple Attention Pathways (class-specific attention score per patch)
Slide Representation	A single aggregated slide-level representation	3 class-specific slide-level representations (Normal , Luad , Lsccl)
Slide-Level Classifier	A single classifier acts on the aggregated slide-level representation	3 parallel classifiers act on 3 class-specific representations
Patch-Level Classifier (Clustering)	A single patch-level objective based on general attention.	N parallel patch-level objectives based on class-specific attention.

3- Deep Learning Model

Single Branch



3- Deep Learning Model

Multi Branch

$$\hat{\mathbf{y}} = [\hat{y}_{\text{Normal}}, \hat{y}_{\text{LUAD}}, \hat{y}_{\text{LSCC}}]$$

$$\mathcal{L}_{\text{slide}} = \text{CrossEntropy}(\hat{\mathbf{y}}, \mathbf{y})$$

Softmax

W_C
Slide-Level
Classifier for
each class

weighted sum

$$\mathbf{Z} = \mathbf{A}^\top \mathbf{H} = \begin{bmatrix} \sum_{k=1}^N a_k^{(\text{Normal})} h_k \\ \sum_{k=1}^N a_k^{(\text{LUAD})} h_k \\ \sum_{k=1}^N a_k^{(\text{LSCC})} h_k \end{bmatrix} = \begin{bmatrix} z^{(\text{Normal})} \\ z^{(\text{LUAD})} \\ z^{(\text{LSCC})} \end{bmatrix}$$

Slide Level

1024 feature
dimensional vector

reduce
dimension

512 feature
dimension vectors

W_1
Dimension
Reducer layer

gated attention mechanism

$$a_{k,c} = \frac{\exp(\mathbf{w}_{a,c}^\top [\tanh(\mathbf{V}_a h_k) \odot \sigma(\mathbf{U}_a h_k)])}{\sum_{i=1}^N \exp(\mathbf{w}_{a,c}^\top [\tanh(\mathbf{V}_a h_i) \odot \sigma(\mathbf{U}_a h_i)])}$$

$A =$

$$\begin{bmatrix} a_1^{(\text{Normal})} & a_1^{(\text{LUAD})} & a_1^{(\text{LSCC})} \\ a_2^{(\text{Normal})} & a_2^{(\text{LUAD})} & a_2^{(\text{LSCC})} \\ \vdots & \vdots & \vdots \\ a_N^{(\text{Normal})} & a_N^{(\text{LUAD})} & a_N^{(\text{LSCC})} \end{bmatrix}$$



Is negative instance

Is positive instance

$$\mathbf{z}_i = W^{y_{clust}} h_i = \begin{bmatrix} z_i^{(0)} \\ z_i^{(1)} \end{bmatrix} \in \mathbb{R}^2$$

$$\mathcal{L}_{\text{patch}} = \text{SmoothTop-1SVM}(\{\mathbf{z}_i\}, \{\tilde{y}_i\})$$

$$\mathcal{L}_{\text{total}} = c_1 \mathcal{L}_{\text{slide}} + c_2 \mathcal{L}_{\text{patch}}$$

$W^{y_{clust}}$
Patch-Level
Classifier for
true class

$$h_k \in \mathbb{R}^{512}$$

K

Select Instance
and assign
pesudo labeling
based on those
attention score

use attention
specific score of
the true class

Patch Level

a_k {
top-k (highest attention)
bottom-K (lowest attention)

Training HyperParameters

Parameter	Value
Maximum epochs	200
Learning rate	0.0002
Optimizer	Adam
Bag loss	Cross-entropy (ce)
Instance loss	Smooth Top-1 SVM (svm)
Bag weight	0.7
Dropout rate	0.25
Early stopping	True



04

Experimental Results



Results | Evaluation Metrics:

Single Branch

Accuracy = 89%



	auc	accuracy	precision	recall	f1_score	specificity
Normal	0.9962455606	0.971153846	0.9466666667	0.9726027397	0.9594594595	0.9703703704
Luad	0.9611516884	0.913461538	0.9152542373	0.8059701493	0.8571428571	0.9645390071
Lsccl	0.9712184874	0.913461538	0.8378378378	0.9117647059	0.8732394366	0.9142857143

Multi Branch

Accuracy = 88%



	auc	accuracy	precision	recall	f1_score	specificity
Normal	0.998782344	0.971153846	0.971830985	0.9452054795	0.9583333333	0.9851851852
Luad	0.96305705	0.894230769	0.816901408	0.8656716418	0.8405797101	0.9078014184
Lsccl	0.970378151	0.903846153	0.86363636	0.8382352941	0.8507462687	0.9357142857

Results |

Single Branch Model

Multi Branch Model

Confusion Matrix


	Actual		
	Normal	Luad	Lscc
Normal	69	3	1
Luad	1	58	8
Lscc	1	10	57

Results | ROC Curve:

Class 0 (Normal): AUC = 1.00

Class 1 (LUAD): AUC = 0.96

Class 2 (LSCC): AUC = 0.97



Pathologist business card



Pathologist validation

Pathologist Validation Report

AI-Generated HeatMap Analysis for Lung Pathology (LungPathAI)

Validating Pathologist: Dr. Khelifi N Ep karasad
Institution/Affiliation: Ex assistante at EPH biskra / CHU at beni messous
Board Certifications: Anatomic Pathology
Date of Validation: 20/05/2025
AI System Under Review: LungPathAI Heat Map
Developers: Ouamane Takieddine, Cherifi Kacem, Gueshaya Islem
Supervisor: ABIR belaal

Cases Reviewed: 10 lung pathology specimens

- Lung Adenocarcinoma (LUAD)
- Lung Squamous Cell Carcinoma (LSCC)
- Normal Lung Tissue

Validation Method: Independent pathologist review comparing AI-generated heat map outputs against standard histopathological assessment.

Based on my review as a board-certified pathologist with expertise in lung pathology, I hereby validate that:

The LungPathAI heat map generation system produces clinically relevant outputs that accurately identify pathologically significant areas in lung tissue specimens.
The heat maps demonstrate sufficient accuracy and clinical utility to serve as an effective diagnostic aid when used under appropriate pathologist supervision.

Recommendation: APPROVED for clinical use as a supplementary diagnostic tool in lung pathology practice.

Limitations: This validation is based on the specific case cohort reviewed. The AI system should be used as an adjunct to, not replacement for, standard pathological assessment. Continued monitoring and periodic revalidation are recommended.




Dr. KHELIFI N EP KARASAD
Date: 15/06/2025


Dr KHELIFI N.
MEDECIN SPECIALISTE EN
ANATOMIE PATHOLOGIQUE

5- Explainability (XAI)

Annotated WSI by expert




Generated Heatmap



Region
of Interest
(High attention)

Overlay





06

Platform Development




Platform Development | Design




Upload WSI



Flask API



Data
Preprocessing



Model response



Regions of Interest

diagnostic
report

Save Diagnosis




Database

User Interface


AI Model

Platform Development | Design


1 – Use Case Diagram



2 – Sequence Diagram (AI Diagnosis Scenario)











07

Conclusion

Conclusion



Leveraging deep learning techniques to enhance Histopathology diagnosis accuracy by training a model on WSIs for lung cancer subtype classification



Provides clinical explainability through attention-based heatmaps




Integrate the validated model into a web application


Future Perspectives



Expanding the dataset from diverse institutions and regions to improve model generalizability



Include multi modal approach by Combining histopathological image features with clinical data




Implementing comprehensive multi-user collaboration features


Thank you



فكرة المشروع




تجاريا ، يقدم المشروع على شكل خدمة طبية تسوق
للمخابر و المستشفيات بشكل أساسي .



سرطان الرئة مرض منتشر و خطير عالميا
ومحليا ، حيث أن نسبة الوفيات من المرض
عالية



إدماج خبرات الأطباء



منصة على الويب توفر خدمة تشخيص السرطان عن
طريق صور الشرائح الكاملة (WSIs)

تحليل SWOT

نقاط القوة

- استخدام الذكاء الاصطناعي.
- انشاء خرائط حرارية.
- منصة متكاملة سهلة الاستخدام
- عدم وجود منافسين مباشرين
- دعم القرار الطبي.

S

نقاط الضعف

- محدودية الموارد المالية و البشرية
- نقص الوعي المحلي.
- تحديات في الحصول على تراخيص رسمية
- الحاجة إلى بيانات طبية.

W

الفرص

- الشراكة مع المؤسسات الصحية
- قلة المنافسة في السوق المحلية
- ازدياد الاهتمام بالتحول الرقمي.
- دعم المشاريع المبتكرة والتكنولوجيا من قبل الحكومة
- إمكانية التوسع

O

التحديات

- دخول شركات أجنبية
- التردد في اعتماد تقنيات الذكاء الاصطناعي
- القيود القانونية المرتبطة باستخدام الذكاء الاصطناعي

T

نموذج العمل التجاري BMC

الشركاء	الأنشطة الرئيسية	القيمة المقدمة	العلاقات مع الزبائن	شرائح العملاء
<div>جامعة بسكرة</div> <div>المصحات والمستشفيات</div> <div>مراكز البحث</div> <div>جمعيات و منظمات الأمراض والأورام</div>	<div>البحث والتطوير</div> <div>تصميم وتطوير نماذج الذكاء الاصطناعي</div> <div>تقييم نتائج النموذج من خلال المخابر</div> <div>تطوير تطبيق الويب</div>	<div>تحديد نوع سرطان الرئة</div> <div>الكشف عن المناطق المتضررة بالسرطان</div> <div>استخدام خوارزميات التعلم العميق</div> <div>واجهة مستخدم سهلة الاستعمال</div> <div>تقليل وقت التشخيص بشكل ملحوظ.</div> <div>أمان بيانات المرضى</div>	<div>الشبكات الإجتماعية</div> <div>لمشاركة التحديثات وتلقي المقترحات</div> <div>الموقع الإلكتروني الخاص بالخدمة</div> <div>دعم فني متخصص</div>	<div>أخصائي علم الأمراض (Pathologists)</div> <div>مخابر التحاليل والتشخيص</div> <div>المصحات</div> <div>طالب الطب والباحثون</div>
	الموارد الرئيسية		القنوات	
	<div>اشتراكات الخدمات السحابية</div> <div>أدوات وبرامج تطوير البرمجيات</div> <div>فريق التطوير</div>		<div>المؤتمرات الطبية والمعارض</div> <div>التسويق بالمحتوى</div> <div>اشتراكات عبر الإنترنت</div> <div>شراكات مع المخابر</div>	
التكاليف			مصادر الإيرادات	
<div></div>			<div>تحديث النماذج</div>	<div>الإشتراكات</div> <div>نموذج Freemium</div> <div>عقود الخدمة و الصيانة</div>
			<div>نفقات البحث والتطوير</div> <div>التسويق</div> <div>تكاليف الخدمات السحابية</div>	